Lan Wang1, You-Ming Li. 1. The First Affiliated Hospital, Medical College, Zhejiang University, Zhejiang Province, China.
Abstract
AIM: To evaluate the efficacy and safety of Heller myotomy (HM) for recurrent achlasia, performed after different methods of first-line treatment. METHODS: We searched for studies published in PubMed from 1966 to March 2008 on treatment of recurrent achalasia with HM after failure with different methods of first-line treatment. The efficacy of HM was assessed by a pooled estimate of response rate with individual studies weighted proportionally to sample size. RESULTS: Sixteen studies were eligible and included in the review. The results showed that HM has a better remission rate for recurrent achalasia after failure of HM [weighted mean (SD)] of 86.9% (21.8%) compared with 81.6% (23.8%) for pneumatic dilatation (PD). One study evaluated the efficacy of HM after failure of PD combined with botulinum toxin injection (83%). The most common complications were perforation and gastroesophageal reflux. CONCLUSION: HM has the best efficacy in patients with recurrent achlasia who were treated with HM as first-line treatment. Future studies should focus on how to increase the success rate and decrease the complications of HM.
AIM: To evaluate the efficacy and safety of Heller myotomy (HM) for recurrent achlasia, performed after different methods of first-line treatment. METHODS: We searched for studies published in PubMed from 1966 to March 2008 on treatment of recurrent achalasia with HM after failure with different methods of first-line treatment. The efficacy of HM was assessed by a pooled estimate of response rate with individual studies weighted proportionally to sample size. RESULTS: Sixteen studies were eligible and included in the review. The results showed that HM has a better remission rate for recurrent achalasia after failure of HM [weighted mean (SD)] of 86.9% (21.8%) compared with 81.6% (23.8%) for pneumatic dilatation (PD). One study evaluated the efficacy of HM after failure of PD combined with botulinum toxin injection (83%). The most common complications were perforation and gastroesophageal reflux. CONCLUSION: HM has the best efficacy in patients with recurrent achlasia who were treated with HM as first-line treatment. Future studies should focus on how to increase the success rate and decrease the complications of HM.
Authors: V Annese; G Bassotti; G Coccia; M Dinelli; V D'Onofrio; G Gatto; G Leandro; A Repici; P A Testoni; A Andriulli Journal: Gut Date: 2000-05 Impact factor: 23.059
Authors: Benjamin R Veenstra; Ross F Goldberg; Steven P Bowers; Mathew Thomas; Ronald A Hinder; C Daniel Smith Journal: Surg Endosc Date: 2015-08-15 Impact factor: 4.584
Authors: Sean B Orenstein; Siavash Raigani; Yuhsin V Wu; Eric M Pauli; Melissa S Phillips; Jeffrey L Ponsky; Jeffrey M Marks Journal: Surg Endosc Date: 2014-09-24 Impact factor: 4.584